New drug KR23343 enters first human safety trials
NCT ID NCT07409922
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early-stage trial tests the safety and tolerability of a new drug called KR23343 in 92 healthy adults aged 18 to 45. Participants receive either the drug or a placebo, and researchers monitor for side effects, lab changes, and how the drug moves through the body. The study also checks if food affects drug levels. This is a Phase 1 study, so the main goal is safety, not treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KR23343
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test